ABOLOGIX awarded a two year Innosuisse Innovation

Geneva, Switzerland, Juy 24, 2020.


Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied by Abologix. These studies will lead to a deeper understanding of the molecular mechanisms of JAM-C blockage to inhibit growth and metastasis of certain lymphomas.

Copyright © 2021 ABOLOGIX